Zymeworks (ZYME) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 May, 2026Executive summary
Annual meeting scheduled for December 30, 2025, at 9:00 a.m. Pacific Time, to be held virtually via the Internet.
Proxy materials, including the Notice, Proxy Statement, and Annual Report on Form 10-K, are available online for review and voting.
Shareholders are encouraged to review all proxy materials before voting and can request paper or email copies at no cost.
Voting matters and shareholder proposals
Election of three directors: Carlos Campoy, Alessandra Cesano, and Robert E. Landry.
Advisory vote on the compensation of named executive officers.
Ratification of KPMG LLP as auditors for the year ending December 31, 2025.
Board recommends voting FOR all nominees and proposals.
Board of directors and corporate governance
Board of Directors has nominated three individuals for election at the annual meeting.
Recommendations and voting instructions are provided to ensure shareholder participation.
Latest events from Zymeworks
- Annual meeting to vote on directors, executive pay, auditor, and highlight ESG and governance.ZYME
Proxy filing18 May 2026 - Key votes include director elections, executive pay, and auditor ratification at the 2024 meeting.ZYME
Proxy filing18 May 2026 - Board recommends approval of all proposals, with strong focus on governance and performance-based pay.ZYME
Proxy filing18 May 2026 - Q3 revenue up 73% on milestone and royalty gains, with narrowed net loss and strong cash runway.ZYME
Q3 202518 May 2026 - FDA Priority Review, $250M royalty loan, and robust pipeline drive long-term value.ZYME
Q1 202618 May 2026 - Robust pipeline advances and strong cash position drive a royalty-focused growth strategy.ZYME
The Citizens Life Sciences Conference 202615 May 2026 - Hybrid biotech-royalty model, strong pipeline, and $250M financing drive growth and flexibility.ZYME
TD Cowen 46th Annual Health Care Conference28 Apr 2026 - Strong financials and innovation drive growth, with key catalysts and pipeline advances ahead.ZYME
2026 Bloom Burton & Co. Healthcare Investor Conference21 Apr 2026 - Transitioning to a hybrid R&D and asset aggregation model, with strong cash and pipeline momentum.ZYME
25th Annual Needham Virtual Healthcare Conference15 Apr 2026